

# Medical Marijuana, Inc.

22:43 02 Jul 2015

## Medical Marijuana makes sizeable investment in Axim Biotech

Shares of Medical Marijuana (OTCMKTS:MJNA), a leading Medical Marijuana developer and distributor, were trading 6.1% higher today after announcing a sizeable investment in Axim Biotechnologies, buying 14,943,650 shares of its common stock and 500,000 shares of preferred stock.

The investment is intended to add diversity to the company's growing portfolio of products and companies. Recently, MJNA's subsidiary Dixie Botanicals, noted for its cannabidiol (CBD hemp oil) products, started producing and selling peppermint flavored hemp stalk oil dew Drops, claimed to promote overall wellness. This is but one example of its reputation as employing formulation experts, able to produce a variety of products from CBD hemp oils.

"We are extremely excited to announce our strategic ownership interest in AXIM Biotech and explain to MJNA's shareholders some of the important innovations that Dr. Anastassov and the AXIM team are focused on. AXIM Biotech's recent announcements include hemp-based innovations that provide consumers a wide variety of new options worldwide," said Medical Marijuana's president and CEO, Dr. Stuart W. Titus.

MJNA's acquisition of AXIM Biotech, a biotechnology company focused on global research, development and production of pharmaceutical, food, nutraceutical and cosmetic products as well as biofuels derived from cannabinoids will complement its recent CBD oils research while developing new proprietary mechanisms for the delivery of cannabinoids.

"AXIM is a unique hemp-derived biosciences corporation where the responsibility for environmental protection and conservation meets the passion for development of innovative biotechnological applications for problems for which there are currently no solutions. The cannabis plant provides ample opportunity for innovative, sometimes revolutionary products. AXIM has realized the vast potential in oral health products based on cannabinoids, in particular CBG, and has filed intellectual property applications to protect its numerous IP," said Axim Biotech's CEO, Dr. George E. Anastassov.

AXIM Biotech owns an exclusive license for the world's first controlled-release cannabinoid chewing gum, available in food, CanChew Plus(R), and pharmaceutical MedChew RX formulations. The product, which addresses two separate markets, is already undergoing clinical trials ahead of registration with the US Food and Drug Administration. AXIM also recently released CBG based oral care products ORAXIMAX and RENECANN.

AXIM Biotech has even more ambitious plans to develop active pharmaceutical ingredients (API) to treat Parkinson's disease, Alzheimer's disease, glaucoma,

**Price:** 0.023

**Market Cap:** \$41.06 m

### 1 Year Share Price Graph



### Share Information

**Code:** MJNA

**Listing:**

52 week	High	Low
	0.0919	0.02

**Sector:** Pharma & Biotech

**Website:** [medicalmarijuanainc.com](http://medicalmarijuanainc.com)

### Company Synopsis:

*Medical Marijuana is comprised of a diversified portfolio of products, services, technology and businesses solely focused on the cannabis and hemp industries. These products range from patented and based cannabinoid products, to whole plant or isolated high value extracts specifically manufactured and formulated for the pharmaceutical, nutraceutical and cosmeceutical industries.*

[action@proactiveinvestors.com](mailto:action@proactiveinvestors.com)

Crohn's disease and many others based on its proprietary IP.

Meanwhile, Medical Marijuana is taking part at HempMeds, New York's Cannabis World Congress & Business Expo. The State of New York is slated to be one of the next states to legalize Medical Marijuana, allowing the cultivation, distribution and usage of Medical Marijuana in New York City.

Medical Marijuana's CEO, Titus, is optimistic about New York's progress toward legalizing cannabis, even if he believes that a successful outcome will still take over a year.

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 [action@proactiveinvestors.com](mailto:action@proactiveinvestors.com)

#### No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.